Cormorant Asset Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Cormorant Asset Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,000	Closed	-$1.02M	–	81
2019 Q3	$1.02M	Buy	+1,000	New	+$31.5K	0.06%	69
2019 Q1	–	Sell	-994,287	Closed	-$19M	–	74
2018 Q4	$19M	Buy	994,287 +353,806	+55%	+$13.3M	1.55%	22
2018 Q3	$33.5M	Sell	640,481 -79,504	-11%	-$4.34M	2.18%	17
2018 Q2	$31.3M	Hold	719,985	–	–	2.32%	14
2018 Q1	$26.7M	Sell	719,985 -177,520	-20%	-$4.74M	1.99%	13
2017 Q4	$17.8M	Hold	897,505	–	–	1.86%	18
2017 Q3	$22.3M	Buy	897,505 +417,519	+87%	+$7.71M	3.94%	7
2017 Q2	$8.37M	Buy	+479,986	New	+$8.4M	1.39%	23

Other funds holding GTHX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Cormorant Asset Management's GTHX Position: Q4 2019 in Review

Cormorant Asset Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2019, closing a stake of 1,000 shares — an estimated $1.02M sold.

Cormorant Asset Management first reported a position in GTHX in Q2 2017 and held it in 8 quarters. The position peaked at $33.5M in Q3 2018. 98 funds tracked by Wall St. Rank hold GTHX as of Q4 2019.

Cormorant Asset Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Cormorant Asset Management sold 1,000 G1 Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1.02M.
Cormorant Asset Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 8 quarters.
Cormorant Asset Management's G1 Therapeutics, Inc. Common Stock position peaked at $33.5M in Q3 2018.
98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.